Calendario›BIIB›Cylex

Cylex

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

Ensayo de BIOGEN INC. en Esclerosis multiple.

Más ensayos de: Esclerosis múltiple.

Fase

no aplica

Estado

Completado

Participantes

100

previstos

Centros

1

Fin del objetivo primario

dic 2008

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en mar 2008.

Qué mide

El objetivo principal de este estudio es determinar los efectos de varias terapias (inmunomoduladoras asi como inmunosupresoras) sobre los niveles de ATP en celulas CD4+. (1 blood draw) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following: * Use a new method called the "Immuknow®" Test to see if this method will help to better understand how MS medicines work. * Measure certain levels of immune cells in a new way, to see if it this will help to understand the body's response to MS medicines. These methods will test those with MS who are not taking any MS medications, to help us compare the results. About 100 subjects will be enrolled in this study at the Partners Multiple Sclerosis Center at Brigham and Women's Hospital. Biogen Idec, Inc. of Cambridge, MA, is paying for this study to be done.

Más ensayos de BIIB

Todos los de BIIB, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00618267), actualizada en mar 2010.